New liver drug tested for heart risks in healthy people
NCT ID NCT07263152
First seen Jan 11, 2026 · Last updated May 11, 2026 · Updated 19 times
Summary
This study checked whether a single dose of hydronidone, a drug being developed for liver scarring (hepatic fibrosis), affects the heart's electrical activity (QTc interval). 48 healthy Chinese adults took either a low, medium, or high dose of the drug or a placebo. The main goal was to see how the drug levels in blood relate to any changes in heart rhythm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Gobroad Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.